SCHEDULE 13D/A: Lipella Pharmaceuticals Officer Michael Chancellor Discloses 10% Beneficial Ownership Stake
Beneficial Ownership Update
Michael B. Chancellor, Chief Medical Officer and Director of Lipella Pharmaceuticals Inc., has updated his beneficial ownership to 10.0% of the company's common stock, totaling 209,640 shares.
Summary
- Michael B. Chancellor, Chief Medical Officer and a member of the Board of Directors of Lipella Pharmaceuticals Inc., has filed Amendment No. 7 to his Schedule 13D.
- This amendment updates his beneficial ownership in Lipella Pharmaceuticals Inc. to 209,640 shares of Common Stock.
- This represents 10.0% of the Issuer's outstanding Common Stock, based on 2,005,244 shares outstanding as of the date of this amendment.
- His beneficial ownership consists of 109,703 shares purchased with personal funds and 99,937 shares issuable upon exercise of fully vested stock options awarded by the Issuer.
- The filing confirms that the Reporting Person has not engaged in any transactions with respect to the Issuer's Common Stock during the sixty days prior to the filing date of this amendment.
- The purpose of this Amendment No. 7 is solely to update the Reporting Person's beneficial ownership percentage.
Sentiment
Score: 7
Explanation: The document indicates a significant insider stake, which is generally positive for investor confidence as it suggests alignment of interests between management and shareholders. However, it is a routine regulatory filing and does not contain new operational or financial news that would significantly alter the company's outlook.
Positives
- A key insider, Michael B. Chancellor, holds a significant 10.0% stake in the company, indicating strong alignment of interests with shareholders.
- A substantial portion of his ownership (109,703 shares) was acquired through personal funds, demonstrating direct financial commitment and confidence in the company.
- The remaining shares (99,937) are from fully vested stock options, reflecting long-term engagement and potential belief in future performance.
Future Outlook
The document is an ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial outlook.
Industry Context
This filing is a routine insider ownership disclosure and does not provide specific details that allow for a broader analysis of industry trends or competitive positioning. It primarily reflects an individual's stake in the company, which is a common occurrence in publicly traded entities.
Stakeholder Impact
- Shareholders: The disclosure of a significant insider stake (10.0%) by a key executive and director may be viewed positively, indicating management's vested interest and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2022-12-29 | Initial Schedule 13D filed by the Reporting Person. |
| 2023-06-21 | Amendment No. 1 to Schedule 13D filed. |
| 2024-03-06 | Amendment No. 2 to Schedule 13D filed. |
| 2024-03-15 | Amendment No. 3 to Schedule 13D filed. |
| 2024-08-19 | Amendment No. 4 to Schedule 13D filed. |
| 2024-10-17 | Amendment No. 5 to Schedule 13D filed. |
| 2025-01-23 | Amendment No. 6 to Schedule 13D filed. |
| 2025-01-28 | Date of event which required the filing of Amendment No. 7. |
| 2025-01-30 | Date of filing of Amendment No. 7. |
Keywords
Lipella Pharmaceuticals Inc., Michael B. Chancellor, Schedule 13D, Beneficial Ownership, Insider Ownership, Common Stock, SEC Filing, LPPM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.